Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis

Chronic pruritus is a cardinal symptom of the inflammatory skin disease atopic dermatitis (AD). Pathogenic mechanisms in the periphery, spinal cord and the brain have been implicated in AD-related pruritus. Therefore, both systemic and topical administration of drugs could potentially provide relief...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of pharmacology 2020-08, Vol.881, p.173242-173242, Article 173242
Hauptverfasser:	Soeberdt, Michael, Kilic, Ana, Abels, Christoph
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Cutaneous Analgesics, Opioid - therapeutic use Animals Antipruritics - administration & dosage Antipruritics - therapeutic use Dermatitis, Atopic - drug therapy Dermatitis, Atopic - metabolism Dermatitis, Atopic - physiopathology Humans Janus kinase inhibitor Janus Kinase Inhibitors - therapeutic use Kappa-opioid receptor agonist Molecular Targeted Therapy Mu-opioid receptor antagonist Narcotic Antagonists - therapeutic use Neurokinin 1 receptor antagonist Neurokinin-1 Receptor Antagonists - therapeutic use Phosphodiesterase 4 inhibitor Phosphodiesterase 4 Inhibitors - therapeutic use Pruritus - drug therapy Pruritus - metabolism Pruritus - physiopathology Receptors, Opioid, kappa - agonists Receptors, Opioid, kappa - metabolism Receptors, Opioid, mu - antagonists & inhibitors Receptors, Opioid, mu - metabolism Signal Transduction Skin - drug effects Skin - innervation Skin - metabolism Topical treatment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!